
The study evaluated the mental health effects of elexacaftor/tezacaftor/ivacaftor (ETI) in 81 pediatric cystic fibrosis (CF) patients over 18 months. At baseline, most participants had normal mental health scores. Among those with elevated anxiety and depression, symptoms significantly decreased during the study period, with only 2–3% showing depressive symptoms and 0% experiencing anxiety by 18 months.
Like
Save
Share